World Health Organization. Prevention and control of viral hepatitis infection: framework for global action. Geneva: World Health Organization; 2012.
Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington, D.C.: The National Academies Press; 2010.
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C: The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–32.
Bell BP, Manos MM, Zaman A, et al. The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am J Gastroenterol. 2008;103:2727–36 (quiz 2737).
Manos MM, Leyden WA, Murphy RC, et al. Limitations of conventionally derived chronic liver disease mortality rates: results of a comprehensive assessment. Hepatology. 2008;47:1150–7.
Wise M, Bialek S, Finelli L, et al. Changing trends in hepatitis C-related mortality in the United States, 1995–2004. Hepatology. 2008;47:1128–35.
Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–44.
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.
Jeffers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39:1702–8.
Hepburn MJ, Hepburn LM, Cantu NS, et al. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med. 2004;117:163–8.
Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265–71.
Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–6.
Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology. 2010;139:1865–76.
McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061–9.
Rodis JL, Kibbe P. Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy. Gastroenterol Nurs. 2010;33:368–73.
Fraenkel L, McGraw S, Wongcharatrawee S, et al. Patients’ experiences related to anti-viral treatment for hepatitis C. Patient Educ Couns. 2006;62:148–55.
Taylor-Young P, Hildebrandt E. The multidimensional burden of hepatitis C and its treatment: a case study. Gastroenterol Nurs. 2009;32:180–7.
McNally S, Temple-Smith M, Sievert W, et al. Now, later or never? Challenges associated with hepatitis C treatment. Aust N Z J Publ Health. 2006;30:422–7.
Kinder M. The lived experience of treatment for hepatitis C. Gastroenterol Nurs. 2009;32:401–8.
Hopwood M, Treloar C. The experience of interferon-based treatments for hepatitis C infection. Qual Health Res. 2005;15:635–46.
Grogan A, Timmins F. Patients’ perceptions of information and support received from the nurse specialist during HCV treatment. J Clin Nurs. 2010;19:2869–78.
Sgorbini M, O’Brien L, Jackson D. Living with hepatitis C and treatment: the personal experiences of patients. J Clin Nurs. 2009;18:2282–91.
Gordon N. Similarity of the Adult Kaiser Permanente Membership in Northern California to the insured and general population in Northern California: statistics from the 2007 California Health Interview Survey. In: Internal report. Oakland (CA): Kaiser Permanente Division of Research; 2012.
Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Publ Health. 1992;82:703–10.
Lopez M, Moreno L, Dosal A, et al. Interferon and the fear of needles: a case report. Gastroenterol Nurs. 2011;34:384–8.
Fontana RJ, Bieliauskas LA, Lindsay KL, et al. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology. 2007;45:1154–63.
Grogan A, Timmins F. Side effects of treatment in patients with hepatitis C: implications for nurse specialist practice. Aust J Adv Nurs. 2009;27:70–7.
Chang SC, Ko WS, Wu SS, et al. Factors associated with quality of life in chronic hepatitis C patients who received interferon plus ribavirin therapy. J Formos Med Assoc. 2008;107:454–62.
Cormier M. The role of hepatitis C support groups. Gastroenterol Nurs. 2005;28(3 Suppl):S4–9.
Jessop AB, Cohen C, Burke MM, et al. Hepatitis support groups: meeting the information and support needs of hepatitis patients. Gastroenterol Nurs. 2004;27:163–9.
Galindo L, Maginnis T, Wallace G, et al. Education by peers is the key to success. Int J Drug Policy. 2007;18:411–6.
Blasiole JA, Shinkunas L, Labrecque DR, et al. Mental and physical symptoms associated with lower social support for patients with hepatitis C. World J Gastroenterol. 2006;12:4665–72.
Zickmund S, Ho EY, Masuda M, et al. “They treated me like a leper”: stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med. 2003;18:835–44.
Perrillo R, Rothstein KD, Rubin R, et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat. 2004;11:157–65.
Su J, Brook RA, Kleinman NL, et al. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology. 2010;52:436–42.
DiBonaventura M, Wagner JS, Yuan Y, et al. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ. 2011;14:253–61.
Silveira MJ, Given CW, Cease KB, et al. Cancer carepartners: improving patients’ symptom management by engaging informal caregivers. BMC Palliat Care. 2011;10:21.
Zickmund S, Hillis SL, Barnett MJ, et al. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology. 2004;39:999–1007.
Gujral H, Viscomi C, Collantes R. The role of physician extenders in managing patients with chronic hepatitis C. Cleve Clin J Med. 2004;71(Suppl. 3):S33–7.
Smith JP, Dong MH, Kaunitz JD. Evaluation of a pharmacist-managed hepatitis C care clinic. Am J Health Syst Pharm. 2007;64:632–6.
Smith JP. Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events. Pharmacotherapy. 2008;28:1151–61.
Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006;101:2254–62.
Silberbogen AK, Ulloa E, Mori DL, et al. A telehealth intervention for veterans on antiviral treatment for the hepatitis C virus. Psychol Serv. 2012;9:163–73.
Ho SB, Groessl E, Dollarhide A, et al. Management of chronic hepatitis C in veterans: the potential of integrated care models. Am J Gastroenterol. 2008;103:1810–23.
Evon DM, Simpson K, Kixmiller S, et al. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol. 2011;106:1777–86.
Yee HS, Chang MF, Pocha C, et al. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 2012;107:669–89 (quiz 690).
Sharma P, Lok AS. Interferon-free treatment regimens for hepatitis C: are we there yet? Gastroenterology. 2011;141:1963–7.
Poordad F, Chee GM. Interferon free hepatitis C treatment regimens: the beginning of another era. Curr Gastroenterol Rep. 2012;14:74–7.
Horberg MA, Hurley LB, Towner WJ, et al. Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2012;60:183–90.